{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:43:09Z","timestamp":1780620189953,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-86727"],"award-info":[{"award-number":["MOP-86727"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"Medical Research and Materiel Command","doi-asserted-by":"publisher","award":["DAMD17-01-1-0729"],"award-info":[{"award-number":["DAMD17-01-1-0729"]}],"id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["199600"],"award-info":[{"award-number":["199600"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["400281"],"award-info":[{"award-number":["400281"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia","award":["Multi-state application numbers 191, 211, and 182"],"award-info":[{"award-number":["Multi-state application numbers 191, 211, and 182"]}]},{"name":"Nationaal Kanderplan"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA58598, N01-CN-55424 and N01-PC-67001"],"award-info":[{"award-number":["R01-CA58598, N01-CN-55424 and N01-PC-67001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA61107"],"award-info":[{"award-number":["R01-CA61107"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA54419, P50-CA136393"],"award-info":[{"award-number":["R01-CA54419, P50-CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA15083"],"award-info":[{"award-number":["P30-CA15083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA193965"],"award-info":[{"award-number":["R01-CA193965"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["SIOP-06-258-01-COUN"],"award-info":[{"award-number":["SIOP-06-258-01-COUN"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000124"],"award-info":[{"award-number":["UL1TR000124"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","award":["94 222 52"],"award-info":[{"award-number":["94 222 52"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Mermaid I project"},{"DOI":"10.13039\/100007048","name":"Mayo Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fred C. and Katherine B. Andersen Foundation"},{"name":"Sherie Hildreth Ovarian Cancer Foundation"},{"name":"Herlev Hospitals Forskningsr\u00e5d, Direkt\u00f8r Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsr\u00e5d"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C536\/A13086, C536\/A6689"],"award-info":[{"award-number":["C536\/A13086, C536\/A6689"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Imperial Experimental Cancer Research","award":["C1312\/A15589"],"award-info":[{"award-number":["C1312\/A15589"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s10552-016-0841-3","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T04:33:53Z","timestamp":1483418033000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium"],"prefix":"10.1007","volume":"28","author":[{"given":"Ana","family":"Babic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Steed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Johnatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"deFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diether","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc T.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoyo","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen L.","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Pejovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moffitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrid","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"841_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/ijc.10250","volume":"98","author":"BW Yin","year":"2002","unstructured":"Yin BW, Dnistrian A, Lloyd KO (2002) Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98:737\u2013740","journal-title":"Int J Cancer"},{"key":"841_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jnci\/djp438","volume":"102","author":"GL Anderson","year":"2010","unstructured":"Anderson GL, McIntosh M, Wu L et al (2010) Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102:26\u201338","journal-title":"J Natl Cancer Inst"},{"key":"841_CR3","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1096\/fj.14-257352","volume":"28","author":"D Haridas","year":"2014","unstructured":"Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK (2014) MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J 28:4183\u20134199","journal-title":"FASEB J"},{"key":"841_CR4","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","volume":"22","author":"KL Terry","year":"2016","unstructured":"Terry KL, Schock H, Fortner RT et al (2016) A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res 22:4664\u20134675","journal-title":"Clin Cancer Res"},{"key":"841_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","volume":"4","author":"DW Cramer","year":"2011","unstructured":"Cramer DW, Bast RC Jr, Berg CD et al (2011) Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4:365\u2013374","journal-title":"Cancer Prev Res (Phila)"},{"key":"841_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","volume":"867","author":"P Bottoni","year":"2015","unstructured":"Bottoni P, Scatena R (2015) The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867:229\u2013244","journal-title":"Adv Exp Med Biol"},{"key":"841_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295\u20132303","journal-title":"JAMA"},{"key":"841_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A et al (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387:945\u2013956","journal-title":"Lancet"},{"key":"841_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0936-6555(05)81038-6","volume":"3","author":"NG Davidson","year":"1991","unstructured":"Davidson NG, Khanna S, Kirwan PH, Bircumshaw D (1991) Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 3:32\u201336","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"841_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/GCO.0b013e3282f2b124","volume":"20","author":"E Hogdall","year":"2008","unstructured":"Hogdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20:4\u20138","journal-title":"Curr Opin Obstet Gynecol"},{"key":"841_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJS Rustin","year":"2010","unstructured":"Rustin GJS, van der Burg MEL, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet 376:1155\u20131163","journal-title":"Lancet"},{"key":"841_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","volume":"110","author":"CC Johnson","year":"2008","unstructured":"Johnson CC, Kessel B, Riley TL et al (2008) The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial. Gynecol Oncol 110:383\u2013389","journal-title":"Gynecol Oncol"},{"key":"841_CR13","first-page":"489","volume":"10","author":"DK Pauler","year":"2001","unstructured":"Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ (2001) Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomar Prev 10:489\u2013493","journal-title":"Cancer Epidemiol Biomar Prev"},{"key":"841_CR14","first-page":"428","volume":"76","author":"C Westhoff","year":"1990","unstructured":"Westhoff C, Gollub E, Patel J, Rivera H, Bast R Jr (1990) CA 125 levels in menopausal women. Obstet Gynecol 76:428\u2013431","journal-title":"Obstet Gynecol"},{"key":"841_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ygyno.2010.08.028","volume":"119","author":"DW Cramer","year":"2010","unstructured":"Cramer DW, Vitonis AF, Welch WR et al (2010) Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol 119:462\u2013468","journal-title":"Gynecol Oncol"},{"key":"841_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/sj.bjc.6604170","volume":"98","author":"CL Pearce","year":"2008","unstructured":"Pearce CL, Wu AH, Gayther SA et al (2008) Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 98:282\u2013288","journal-title":"Br J Cancer"},{"key":"841_CR17","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-06-3261","volume":"67","author":"SA Gayther","year":"2007","unstructured":"Gayther SA, Song H, Ramus SJ et al (2007) Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 67:3027\u20133035","journal-title":"Cancer Res"},{"key":"841_CR18","doi-asserted-by":"publisher","first-page":"815894","DOI":"10.1155\/2013\/815894","volume":"2013","author":"LE Kelemen","year":"2013","unstructured":"Kelemen LE, Kobel M, Chan A, Taghaddos S, Dinu I (2013) Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. BioMed Res Int 2013:815894","journal-title":"BioMed Res Int"},{"key":"841_CR19","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","volume":"111","author":"M Kobel","year":"2014","unstructured":"Kobel M, Madore J, Ramus SJ et al (2014) Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 111:2297\u20132307","journal-title":"Br J Cancer"},{"key":"841_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ijc.23017","volume":"122","author":"MA Merritt","year":"2008","unstructured":"Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170\u2013176","journal-title":"Int J Cancer"},{"key":"841_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.424","volume":"41","author":"H Song","year":"2009","unstructured":"Song H, Ramus SJ, Tyrer J et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996\u20131000","journal-title":"Nat Genet"},{"key":"841_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1677\/ERC-08-0104","volume":"15","author":"MT Goodman","year":"2008","unstructured":"Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME (2008) Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 15:1055\u20131060","journal-title":"Endocr Relat Cancer"},{"key":"841_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/EDE.0b013e31816334c5","volume":"19","author":"G Lurie","year":"2008","unstructured":"Lurie G, Wilkens LR, Thompson PJ et al (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237\u2013243","journal-title":"Epidemiology"},{"key":"841_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, Luck HJ, Meier W et al (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320\u20131329","journal-title":"J Natl Cancer Inst"},{"key":"841_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","volume":"121","author":"P Harter","year":"2011","unstructured":"Harter P, Muallem ZM, Buhrmann C et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121:615\u2013619","journal-title":"Gynecol Oncol"},{"key":"841_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1349-7006.1999.tb00741.x","volume":"90","author":"K Hirose","year":"1999","unstructured":"Hirose K, Tajima K, Hamajima N et al (1999) Comparative case-referent study of risk factors among hormone-related female cancers in Japan. Jpn J Cancer Res 90:255\u2013261","journal-title":"Jpn J Cancer Res"},{"key":"841_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djv347","volume":"108","author":"PD Pharoah","year":"2016","unstructured":"Pharoah PD, Song H, Dicks E, et al (2016) PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. J Natl Cancer Inst 108:1\u20135","journal-title":"J Natl Cancer Inst"},{"key":"841_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2009.01.020","volume":"113","author":"FD Begum","year":"2009","unstructured":"Begum FD, Hogdall E, Kjaer SK et al (2009) Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol 113:221\u2013227","journal-title":"Gynecol Oncol"},{"key":"841_CR29","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/0008-5472.CAN-07-5165","volume":"68","author":"LE Kelemen","year":"2008","unstructured":"Kelemen LE, Sellers TA, Schildkraut JM et al (2008) Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 68:2498\u20132506","journal-title":"Cancer Res"},{"key":"841_CR30","doi-asserted-by":"publisher","first-page":"e10061","DOI":"10.1371\/journal.pone.0010061","volume":"5","author":"JM Schildkraut","year":"2010","unstructured":"Schildkraut JM, Iversen ES, Wilson MA et al (2010) Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 5:e10061","journal-title":"PLoS ONE"},{"key":"841_CR31","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1158\/0008-5472.CAN-04-3885","volume":"65","author":"KL Terry","year":"2005","unstructured":"Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65:5974\u20135981","journal-title":"Cancer Res"},{"key":"841_CR32","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.1158\/0008-5472.CAN-06-0222","volume":"66","author":"T Pejovic","year":"2006","unstructured":"Pejovic T, Yates JE, Liu HY et al (2006) Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 66:9017\u20139025","journal-title":"Cancer Res"},{"key":"841_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1593\/tlo.09199","volume":"2","author":"T Pejovic","year":"2009","unstructured":"Pejovic T, Pande NT, Mori M et al (2009) Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Transl Oncol 2:341\u2013349","journal-title":"Transl Oncol"},{"key":"841_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/prca.200900171","volume":"4","author":"E Hogdall","year":"2010","unstructured":"Hogdall E, Fung ET, Christensen IJ et al (2010) Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteom Clin Appl 4:940\u2013952","journal-title":"Proteom Clin Appl"},{"key":"841_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682\u20131691","journal-title":"J Natl Cancer Inst"},{"key":"841_CR36","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","volume":"25","author":"S Marsh","year":"2007","unstructured":"Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25:4528\u20134535","journal-title":"J Clin Oncol"},{"key":"841_CR37","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"1989","unstructured":"Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York"},{"key":"841_CR38","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","volume":"25","author":"SS Tworoger","year":"2007","unstructured":"Tworoger SS, Eliassen AH, Sluss P, Hankinson SE (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25:1482\u20131488","journal-title":"J Clin Oncol"},{"key":"841_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10552-013-0157-5","volume":"24","author":"RK Matsuno","year":"2013","unstructured":"Matsuno RK, Sherman ME, Visvanathan K et al (2013) Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control 24:749\u2013757","journal-title":"Cancer Causes Control"},{"key":"841_CR40","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1158\/1055-9965.EPI-13-0391","volume":"22","author":"M Kobel","year":"2013","unstructured":"Kobel M, Kalloger SE, Lee S et al (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev 22:1677\u20131686","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"841_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1476-4598-9-118","volume":"9","author":"JA Belisle","year":"2010","unstructured":"Belisle JA, Horibata S, Jennifer GA et al (2010) Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 9:118","journal-title":"Mol Cancer"},{"key":"841_CR42","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.424","volume":"41","author":"H Song","year":"2009","unstructured":"Song H, Ramus SJ, Tyrer J et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996\u20131000","journal-title":"Nat Genet"},{"key":"841_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/ERC-12-0395","volume":"20","author":"CM Olsen","year":"2013","unstructured":"Olsen CM, Nagle CM, Whiteman DC et al (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr-Relat Cancer 20:251\u2013262","journal-title":"Endocr-Relat Cancer"},{"key":"841_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","volume":"13","author":"CL Pearce","year":"2012","unstructured":"Pearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385\u2013394","journal-title":"Lancet Oncol"},{"key":"841_CR45","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh W, Kobel M, Longacre TA et al (2013) Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol 14:853\u2013862","journal-title":"Lancet Oncol"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0841-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-016-0841-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0841-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:13:40Z","timestamp":1589660020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-016-0841-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s10552-016-0841-3","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]},"assertion":[{"value":"16 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}